Drug Profile
Research programme: Micacide protein therapeutics - Xyphos
Alternative Names: MICA-fusion proteins; Micacide™ proteinsLatest Information Update: 06 Jul 2022
Price :
$50
*
At a glance
- Originator AvidBiotics Corp.
- Developer Xyphos
- Class Immunoproteins; Recombinant fusion proteins
- Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Viral infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Viral-infections in USA (Parenteral)
- 01 Nov 2017 AvidBiotics splits itself into two companies, Xyphos to Develop Cell-based Therapeutics for Cancer and Pylum Biosciences that will focus on antibacterial proteins for microbiota management and drug-resistant bacteria